CN104435664A - Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases - Google Patents
Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN104435664A CN104435664A CN201410632859.4A CN201410632859A CN104435664A CN 104435664 A CN104435664 A CN 104435664A CN 201410632859 A CN201410632859 A CN 201410632859A CN 104435664 A CN104435664 A CN 104435664A
- Authority
- CN
- China
- Prior art keywords
- blood
- pharmaceutical composition
- parts
- fluoritum
- semen phaseoli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
Abstract
The invention discloses a red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The red-bean-containing pharmaceutical composition is prepared from raw materials including astragalus, fructus choerospondiatis, sargentgloryvine stems, fluoritum, radix ophiopogonis and red beans. The pharmaceutical composition not only has the effects of promoting blood circulation to remove blood stasis as well as tonifying qi and activating blood circulation, but also has a better effect on treating ischemic cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, specifically the Radix Astragali, Fructus Choerospondiatis, Caulis Sargentodoxae, Fluoritum, Radix Ophiopogonis, Semen Phaseoli are the pharmaceutical composition that raw material is made.
Background technology
Cardiovascular and cerebrovascular disease is middle-aged and elderly people common disease, and especially old people's sickness rate of more than 60 years old is high, and it is long that high fat of blood sends out the time, and greatly, being difficult to radical cure, is one of Etiological that person in middle and old age's cardiovascular and cerebrovascular disease is lethal in blood viscosity change.The traditional Chinese medical science thinks taste virtual loss, dysfunction of the spleen in transportation and transformation, causes that expectorant is turbid to be gathered, qi depression to blood stasis.Wherein empty in QI and blood, be induce into this cause of the hyperlipidemia, because of patient's blood stasis due to qi deficiency, QI and blood is not all right and phlegm-turbidity and blood stasis is stagnant.Middle-aged and elderly people visceral-qi void declines, dysfunction of the spleen in transportation and transformation, and easy in blood expectorant is turbid gathers, and long-pending sick solid for a long time, in daily life once burst thromboembolism, is usually fatal.Though thromboembolism morbidity is at blood vessel, the right cause of disease regulates unstability by the five internal organs six mansion, and expectorant is turbid to be gathered, and phlegm-damp blood stasis is stagnant in middle Jiao, caused by functional activity of QI being not smooth.Its essence is weakened body resistance, and namely yang-energy is not changed, and heresy is life thus, comes and goes with gas.
Summary of the invention
Object of the present invention is just to provide a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, and this pharmaceutical composition can healthy energy, and Eradicates is empty, promoting blood circulation to restore menstrual flow, promotes the mutual transporting between body fluid and QI and blood, patient is got well.
In order to realize foregoing invention object, the invention provides following technical scheme:
Treat a pharmaceutical composition for cardiovascular and cerebrovascular disease, it is raw material composition primarily of the Radix Astragali, Fructus Choerospondiatis, Caulis Sargentodoxae, Fluoritum, Radix Ophiopogonis, Semen Phaseoli.
The present invention is with the Radix Astragali, Fructus Choerospondiatis and Caulis Sargentodoxae, and promoting flow of QI and blood, Eradicates exorcising noxious dampness, increases the transporting between dirty mansion body fluid and QI and blood, is aided with Radix Ophiopogonis and Semen Phaseoli, and the temperature compensation deficiency of vital energy, establishes the yang function and promote the production of body fluid, and blood evacuation of pus.And enter conscience warp with Fluoritum, cold-proofly invade body, QI and blood is with mending, and the transporting of strong QI and blood, effectively treats cardiovascular and cerebrovascular disease, prevents disease relapse, is particularly useful for high thrombosis class cardiovascular and cerebrovascular disease.Preferably only adopt above six kinds of compositions.
Preferably, in pharmaceutical composition of the present invention, the ratio of each component is: Radix Astragali 1-35 part, Fructus Choerospondiatis 1-12 part, Caulis Sargentodoxae 1-12 part, Fluoritum 1-12 part, Radix Ophiopogonis 1-12 part, Semen Phaseoli 1-8 part.The Radix Astragali is main, and Fructus Choerospondiatis and Caulis Sargentodoxae are auxiliary, nourish the gas of this yuan, supplements QI and blood, and Eradicates is except blood stasis, and Radix Ophiopogonis and Semen Phaseoli regulate QI and blood transporting, effectively treat cardiovascular and cerebrovascular disease, do not recur.The present invention realizes the collaborative facilitation between kinds of traditional Chinese medicines, improves the body constitution of patient and the power of meridians transporting greatly, improves the effect for the treatment of cardiovascular and cerebrovascular disease.
Preferably, in pharmaceutical composition of the present invention, the ratio of each component is: Radix Astragali 10-30 part, Fructus Choerospondiatis 2-8 part, Caulis Sargentodoxae 2-8 part, Fluoritum 2-8 part, Radix Ophiopogonis 2-8 part, Semen Phaseoli 1-5 part.In conjunction with the proportioning of the preferred each component of clinical research experience, improve mutual promoting action, reduce the toxic and side effects that medicine is unnecessary.
Most preferred, in pharmaceutical composition of the present invention, the ratio of each component is: the Radix Astragali 18 parts, Fructus Choerospondiatis 6 parts, Caulis Sargentodoxae 6 parts, Fluoritum 6 parts, Radix Ophiopogonis 6 parts, Semen Phaseoli 3 parts.Select the Chinese medicine composition proportioning of aforementioned proportion, best at therapeutic effect, after medication, patient gets well fast, and QI and blood transporting is smooth and easy, and blood stasis no longer recurs.
The cardiovascular and cerebrovascular disease that medicine of the present invention is controlled mainly comprises cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, nerve injury, senile dementia, parkinsonism etc.Be particularly useful for the prevention and therapy of ischemia apoplexy.
Compared with prior art, beneficial effect of the present invention:
The present invention is with the Radix Astragali, Fructus Choerospondiatis and Caulis Sargentodoxae, and promoting flow of QI and blood, Eradicates exorcising noxious dampness, increases the transporting between dirty mansion body fluid and QI and blood, is aided with Radix Ophiopogonis and Semen Phaseoli, and the temperature compensation deficiency of vital energy, establishes the yang function and promote the production of body fluid, and blood evacuation of pus.And enter conscience warp with Fluoritum, cold-proofly invade body, QI and blood is with mending, and the transporting of strong QI and blood, effectively treats cardiovascular and cerebrovascular disease, prevents disease relapse, is particularly useful for high thrombosis class cardiovascular and cerebrovascular disease.Preferably only adopt above six kinds of compositions.
Nourish the gas of this yuan, supplement QI and blood, Eradicates is except blood stasis, and Radix Ophiopogonis and Semen Phaseoli regulate QI and blood transporting, effectively treat cardiovascular and cerebrovascular disease, do not recur.The present invention realizes the collaborative facilitation between kinds of traditional Chinese medicines, improves the body constitution of patient and the power of meridians transporting greatly, improves the effect for the treatment of cardiovascular and cerebrovascular disease.
Detailed description of the invention
Pharmaceutical composition of the present invention, the method by oral, external, injection, infiltration, absorption, physics or chemistry mediation imports body as muscle, Intradermal, subcutaneous, vein or mucosal tissue; Or to be mixed by other material or to import body after wrapping up.
Further, pharmaceutical composition of the present invention, adds medicine acceptable carrier or adjuvant when being prepared into medicament, make pharmaceutically acceptable dosage form.
Pharmaceutical composition of the present invention, according to use needs, can by current usual manner, by described active drug composition auxiliary adding ingredient corresponding to acceptable in medicine, as disintegrating agent, excipient, lubricant, binding agent, filler etc., jointly be prepared into operational, comprise the oral type pharmaceutical preparation of the common formulations such as tablet, drop pill, capsule, micropill.
In Chinese medicine composition of the present invention: the Radix Astragali, sweet in the mouth, slightly warm in nature.Return lung, spleen, liver, kidney channel.Invigorating QI to consolidate the body surface resistance, expelling pus and toxin by strengthening QI, diuresis, granulation promoting., chronic diarrhea proctoptosis, spontaneous perspiration, edema weak for the deficiency of vital energy, sub-official prolapsus, chronic nephritis proteinuria, diabetes, open sore part disunion of a specified duration.Fructus Choerospondiatis, sweet in the mouth, acid, property is put down.Promoting flow of QI and blood, nourishes heart, and calms the nerves.For qi depression to blood stasis, the thoracic obstruction is had a pain, shortness of breath and palpitation, irritability.Caulis Sargentodoxae, bitter in the mouth, property is put down.There is the eliminating carbuncle that relieves internal heat, promoting blood circulation to remove obstruction in the collateral, the effect of wind dispelling insecticide.Control acute and chronic appendicitis, rheumatic arthralgia, bloody dysentery, stranguria with blood, menoxenia, infantile malnutrition, worm pain, injury from falling down.Fluoritum, sweet in the mouth, warm in nature.Enter the heart, Liver Channel.Relieving palpitation, can control asthenia palpitation with fear, cough with dyspnea, women's sea of blood deficiency and coldness is infertile.Radix Ophiopogonis, sweet in the mouth, micro-hardship, cold nature.GUIXIN, lung, stomach warp.YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire.For dryness of the lung dry cough, deficiency of YIN consumptive disease is coughed, sore throat pharyngalgia, and Tianjin wound is thirsty, and interior-heat is quenched one's thirst, vexed insomnia, dryness of the intestine constipation.Semen Phaseoli, diuretic dehumidifies, and blood evacuation of pus, subduing swelling and detoxicating.Harness the river swollen, beriberi, jaundice, dysentery, has blood in stool, carbuncle.
Pharmaceutical composition of the present invention can adopt but be not limited to following methods:
Preparation method one: get the Radix Astragali, Fructus Choerospondiatis, Caulis Sargentodoxae, Fluoritum, Radix Ophiopogonis, Semen Phaseoli in proportion, mixed after pulverizing 40 mesh sieves respectively, after adding the acceptable auxiliary element of appropriate pharmacy, made the oral type pharmaceutical preparatioies such as tablet, capsule or micropill.
Preparation method two: by the Radix Astragali, Caulis Sargentodoxae alcohol reflux, extracting solution is concentrated into dry, obtains extract one.By Fructus Choerospondiatis, Radix Ophiopogonis and Semen Phaseoli soak by water, extracting solution is concentrated into dry, obtains extract two.By Fluoritum pulverizing, cross 40 mesh sieves, obtain Fluoritum powder.By extract one, extract two and Fluoritum powder mix homogeneously, after adding the acceptable auxiliary element of pharmacy as required, make the oral type pharmaceutical preparatioies such as tablet, capsule, drop pill or micropill.
The preferred Radix Astragali, the Caulis Sargentodoxae alcohol reflux 1-3 hour of the 30%-80% of 2-4 times of volume, repeat to extract 2-4 time, extracting solution is concentrated into dry, obtains mixed extract one.
Preferably, by Fructus Choerospondiatis, Radix Ophiopogonis and Semen Phaseoli soak by water 1-4 time with 6-10 times of volume, merge extractive liquid, is concentrated into dry, obtains mixed extract two.
Preparation method three:
Prepare the method for Chinese medicine composition of the present invention, comprise the following steps:
(1) Radix Astragali is added the high concentration ethanol of 4-8 times of volume, reflux, extract, 3 times, each 1 ~ 2 hour, merge extractive liquid, is concentrated into dry, obtains Radix Astragali extract.
(2) getting Fructus Choerospondiatis pulverize at low temperature, to obtain Fructus Choerospondiatis powder for subsequent use.
(3) Caulis Sargentodoxae section is got, add the alcohol reflux 1-2 hour of 30% ~ 50% of 1 ~ 2 times of volume ratio, filter, collect filtrate, repeat to extract once, merging filtrate, filtrate crosses polyamide column, first rinses colourless to effluent with water, use straight alcohol eluting again, collect ethanol elution, be concentrated into dry, obtain Caulis Sargentodoxae extract.
(4) get Fluoritum pulverizing, cross 60 mesh sieves, obtain Fluoritum powder for subsequent use.
(5) dry Radix Ophiopogonis is got, add the Diluted Alcohol of 3 ~ 10 times of volumes, decoct 1 ~ 5 hour, filter, collect filtrate, the filtering residue dense alcohol reflux 1 ~ 2 hour using 1 ~ 2 times of volume again, filter, merging filtrate, the middle ethanol contend percentage ratio adding ethanol adjustment solution reaches more than 80%, supernatant concentration, to dry, obtains Radix Ophiopogonis extract.
(6) getting Semen Phaseoli pulverize at low temperature, to obtain Semen Phaseoli powder for subsequent use.
(7) the various extracts obtained through above-mentioned steps process are mixed in proportion, make tablet.The acceptable adjuvant of appropriate pharmacy can be added according to actual needs.
High concentration ethanol of the present invention or dense ethanol refer to the ethanol water of percent by volume more than 50% ~ 80%.Described Diluted Alcohol refers to the ethanol water of percent by volume below 10% ~ 20%.
Wherein most preferably preparation method three, preparation method three is according to different medicines characteristic separately, select suitable extracting method farthest to be extracted by the effective ingredient in medicinal raw material, avoid the impact of the impurity of toxic side effect, so most preferably preparation method three.
The curative effect of medicine of the present invention and advantage thereof are proved by following pharmacodynamics test:
Test one: pharmacodynamics test rat " rabbit brain powder-macromolecule glucosan " being caused to the therapeutical effect of cerebral infarction
Principle: because cardiovascular and cerebrovascular disease all can cause hemorheological change, so medicine causes the therapeutical effect of cerebral infarction pharmacodynamics test to rat " rabbit brain powder-macromolecule glucosan " can be designed, to measure the change that whole blood viscosity under different shear rate investigates hemorheological property after cerebral infarction, investigate erythrocyte deformability with red blood cell protein ringer solution viscosity, thus investigate medicine to the therapeutical effect of cardiovascular and cerebrovascular disease.
Material: animal: rat, body weight 250-350g, male and female are regardless of.Equipment: cone and plate viscometer, centrifuge, scale centrifuge tube, eye scissors, ophthalmic tweezers and conventional operating theater instruments, 0 trumpeter's art silk thread, vascular clamp etc.
Medicine and reagent: the application medicine 1:(Radix Astragali 18 parts, Fructus Choerospondiatis 6 parts, Caulis Sargentodoxae 6 parts, Fluoritum 6 parts, Radix Ophiopogonis 6 parts, Semen Phaseoli 3 parts, adopts preparation method three to be prepared into tablet);
The application medicine 2:(Radix Astragali 20 parts, Fructus Choerospondiatis 6 parts, Caulis Sargentodoxae 7 parts, Fluoritum 6 parts, Radix Ophiopogonis 5 parts, Semen Phaseoli 3 parts, adopts preparation method two to be prepared into tablet);
The application medicine 3:(Radix Astragali 15 parts, Fructus Choerospondiatis 7 parts, Caulis Sargentodoxae 8 parts, Fluoritum 6 parts, Radix Ophiopogonis 6 parts, Semen Phaseoli 4 parts.Preparation method one is adopted to be prepared into tablet);
The control drug 1:(Radix Astragali 18 parts, Fructus Choerospondiatis 6 parts, Caulis Sargentodoxae 6 parts, Radix Ophiopogonis 6 parts, Semen Phaseoli 3 parts, adopts preparation method two to be prepared into tablet);
The control drug 2:(Radix Astragali 18 parts, Fructus Choerospondiatis 6 parts, Caulis Sargentodoxae 6 parts, adopts preparation method one to be prepared into tablet);
The control drug 3:(Radix Astragali 18 parts, Caulis Sargentodoxae 6 parts, Semen Phaseoli 3 parts, adopts preparation method two to be prepared into tablet);
With commercially available Breviscapini injection for positive drug contrasts; Rabbit brain powder (rabbit brain powder thromboplastin powder).Get the rabbit brain powder between sub-sieve 120-150 order, granule is 100-120m.Macromolecule glucosan: molecular weight 5,000,000.The preparation of suppository: 25mg rabbit brain powder is mixed in 10% macromolecule dextran solution 100ml, is placed in 37 DEG C of water-baths 40 minutes.Then ,-18 DEG C of refrigerators are put in for subsequent use.Rapid Medical ZT glue.BSA, ringer solution.Heparin sodium: add test tube by 20u/ml blood dosage, less than 40 DEG C dry for standby.
Test method: 1, rat cerebral infarction model preparation: rat etherization, lie on the back fixing, skin cropping is sterilized, cervical incision, and on the left of being separated, neck always beats one's brains, neck is interior, external carotid artery.Folder closes external carotid artery, common carotid artery proximal part respectively.A vascular clamp is pressed from both sides again at distal end place.After suppository is shaken up, lunge common carotid artery with 0.25ml syringe by 0.03ml/100g rat dosage, open distal end vascular clamp, suppository is injected.Then, folder closes common carotid artery distal end, extracts syringe needle, bonds pin hole with medical adhesive.Decontrol the vascular clamp of common carotid artery distal end, proximal part, external carotid artery after 1 minute successively, recover blood flow, cleaning wound, skin suture.
Medicine affects the hemorheology of different time after cerebral infarction: rat is divided into 2 hours groups, 3 days groups, 9 days groups, often group is further divided into administration group (application medicine 1 ~ 3 group or control drug 1 ~ 3 group+animal model group), normal saline group (normal saline+animal model group), sham operated rats (matched group), often organizes 12 rats.Administration group, normal saline group impose operation technique all as stated above, and sham operated rats operation technique is identical, but not injected plug agent, replace suppository with normal saline, be injected in internal carotid artery.
Administration group is in operation consent 3 days oral drugs (the application's medicine, control drug) 1.42g/Kg.Positive drug is in operation consent 1 hour intraperitoneal injection of drugs 1.0mg/Kg.Normal saline group injects commensurability normal saline.Sham operated rats does not inject any medicine.Every morning administration 1 time after 3 days groups and 9 days groups, for three days on end or 9 days.
2 hours after surgery, the 3rd day, the 9th day respectively, by rat anesthesia (25% urethane 0.3ml/100g body weight, lumbar injection), right common carotid artery blood-letting, in heparin test tube, measured the whole blood viscosity under different shear rate with cone and plate viscometer in 2 hours.Again that whole blood is centrifugal with 1500rpm, suck upper plasma.Then 0.25% bovine serum albumin-ringer solution rinsing erythrocyte three times is used, centrifugal 10 minutes of each 1500rpm.Finally, be in vitro mixed with erythrocyte at scale: albumen appoints the red blood cell protein ringer solution of liquid=6:4, measure its viscosity at 20 seconds under-1 shear rate.Using red blood cell protein ringer solution viscosity as erythrocyte deformability.All experiments are all carried out under 25 DEG C of constant temperature, carry out statistical test to experimental result.Concrete numerical value and the results are shown in Table one, table two.
Table one: the whole blood viscosity of different time after rat cerebral infarction is affected (unit: mPa.s)
From table one result of the test, after blocking latter 2 hours, whole blood viscosity respectively organizes equal no significant difference.When blocking 3 days, normal saline group is compared with sham operated rats, and whole blood viscosity rises (P<0.05), and animal model modeling success is described.Each administration group all can reduce whole blood viscosity to some extent, and wherein with the application's effect of drugs best (P<0.01, compared with normal saline group), control drug effect is taken second place.When blocking after 9 days, normal saline group is still abnormality with sham operated rats ratio, hemorheology, and whole blood viscosity increases the weight of further.Each administration group and normal saline group ratio, whole blood viscosity declines, and statistical procedures has significant, and wherein with the application's effect of drugs best (P<0.01), control drug effect is taken second place.
Table two: on the impact (unit: mPa.s) of different time erythrocyte-albumen ringer solution viscosity
From table two result of the test, after blocking latter 2 hours, normal saline group and administration group erythrocyte deformability decline, and each administration group is slightly lower than normal saline group numerical value, but effect is very unobvious.When blocking 3 days, normal saline group is compared with sham operated rats, and erythrocyte deformability declines further, all can erythrocyte deformability be stoped to a certain extent to decline in each administration group, the application's effect of drugs best (P<0.01).When blocking after 9 days, normal saline group and sham operated rats ratio, erythrocyte deformability further declines.Each administration group and normal saline group ratio, all can improve and stop the decline of erythrocyte deformability, statistical procedures has significant (P<0.01), wherein can strengthen erythrocyte deformability with the application's medicine.
In sum, perform the operation after 2 hours, rat has hemorheological exception.Infraction 3-9 days, Abnormal Blood Rheology increases the weight of further, shows as whole blood viscosity and raises, degradation under erythrocyte deformability.The application's medicine can play and improve hemorheological property effect after cerebral infarction, after the 3rd day, then can correct abnormal hemorheology change significantly.And successful is better than control drug, be also better than commercially available Breviscapini injection.
Test two: on senile rat in the thrombotic impact of body
Principle: use unidirectional current continued stimulus common carotid artery 7 minutes, cause blood vessel internal membrane damage, activate platelet and blood coagulation system, simultaneously vascular endothelial cell injury, makes the synthesis of PGI2 and release reduce, causes in carotid artery vascular and form mixed thrombus gradually.When carotid artery vascular endogenous cause of ill thrombosis during plug flow, then blood vessel distal temperature bust.By temperature sensor monitors blood vessel surface variations in temperature, by instrument automatic alarm, record to sudden temperature drop required time from stimulation, claim duration of congestion OT, i.e. thrombus formation time.Time is shorter, represents and more easily forms thrombosis; Otherwise the time is longer, represents and more not easily form thrombosis.
Senile rat can self-assembling formation blood stasis body constitution, easily forms thrombus in vivo.Young rat then not easily forms thrombosis.Therefore be positive control with senile rat in test, take young rat as negative control.
Material: male rat.Younger group Mus 3-4 in the age month, about body weight 250g.Old group Mus 24-27 in the age month, about body weight 500g.Equipment: rat operation platform, operating scissors, ophthalmic tweezers, mosquito forceps, mosquito clamp, rat oral gavage syringe needle, instrument for detecting internal thrombosis.Medicine and reagent: the application's medicine and control drug are with test one, and dosage is 1.42g/Kg; 20mg/ml Nembutal sodium solution; Normal saline.
Method: only give experimental group every day old group rat oral gavage 2ml/, positive controls senile rat and negative control group young rat gavage distilled water 2ml/ only, continuous 14 days.Drug withdrawal fasting on the same day.Lumbar injection 20mg/ml pentobarbital sodium 0.2ml/100g next day (body weight).Cut skin of neck, be separated right carotid artery, transfer stimulating electrode at carotid artery near-end, far-end transfers the temperature gauge head connecting instrument.Open instrument switch, give 1.5mV galvanic stimulation 7 minutes to damage carotid artery endotheliocyte by stimulating electrode, along with carotid canal intracavity thrombosis is formed gradually, blood flow is blocked gradually, and the temperature of carotid artery far-end declines gradually.When blood flow blocks completely, sudden temperature drop, instrument alarm, display duration of congestion OT, the OT time is shorter, more easily forms thrombosis; The OT time is longer, more not easily forms thrombosis.
Statistical test is carried out to experimental result.Concrete numerical value and the results are shown in Table three.
Table three: on senile rat in the thrombotic impact of body
From table three result of the test, senile rat OT is obviously short compared with young rat, illustrates and easily forms thrombosis.Administration group all can significant prolongation OT, and the application's effect of drugs better (P<0.01).
Above result shows, the application's medicine is effective compared with control drug.
Below in conjunction with detailed description of the invention, the present invention is described in further detail.Percentage ratio not specified in the present invention is all weight percentage.
Embodiment 1
Get Radix Astragali 18kg, Fructus Choerospondiatis 6kg, Caulis Sargentodoxae 6kg, Fluoritum 6kg, Radix Ophiopogonis 6kg, Semen Phaseoli 3kg, after pulverizing 40 mesh sieves respectively, mix homogeneously, makes capsule.
Embodiment 2
Obtain mixed powder by the method for embodiment 1, make capsule casing material with gelatin, be pressed into soft capsule.
Embodiment 3
By Radix Astragali 30kg, Caulis Sargentodoxae 8kg alcohol reflux, extracting solution is concentrated into dry, obtains extract one.By Fructus Choerospondiatis 8kg, Radix Ophiopogonis 2kg and Semen Phaseoli 5kg soak by water, extracting solution is concentrated into dry, obtains extract two.By Fluoritum pulverizing 2kg, cross 40 mesh sieves, obtain Fluoritum powder.By extract one, extract two and Fluoritum powder mix homogeneously, after adding the acceptable auxiliary element of pharmacy as required, make the oral type pharmaceutical preparatioies such as tablet, capsule, drop pill or micropill.
Embodiment 4
Proportioning raw materials consumption is identical with embodiment 3, and be the alcohol reflux 1-3 hour of the Radix Astragali, the Caulis Sargentodoxae 30%-80% of 2-4 times of volume, repeat to extract 2-4 time, extracting solution is concentrated into dry, obtains mixed extract one.By Fructus Choerospondiatis, Radix Ophiopogonis and Semen Phaseoli soak by water 1-4 time with 6-10 times of volume, merge extractive liquid, is concentrated into dry, obtains mixed extract two.All the other steps are also identical with embodiment 3.
Embodiment 5
Implementation process is with embodiment 1, and just raw material dosage is: Radix Astragali 30kg, Fructus Choerospondiatis 2kg, Caulis Sargentodoxae 8kg, Fluoritum 8kg, Radix Ophiopogonis 8kg, Semen Phaseoli 1kg.
Embodiment 6
By Radix Astragali 18kg, add the high concentration ethanol of 8 times of volumes, reflux, extract, 3 times, each 2 hours, merge extractive liquid, is concentrated into dry, obtains Radix Astragali extract.Get Fructus Choerospondiatis 6kg, it is for subsequent use that pulverize at low temperature obtains Fructus Choerospondiatis powder.Get Caulis Sargentodoxae 6kg, section, add the alcohol reflux 2 hours of 30% of 2 times of volume ratios, filter, collect filtrate, repeat to extract once, merging filtrate, filtrate crosses polyamide column, first rinse colourless to effluent with water, then use straight alcohol eluting, collect ethanol elution, be concentrated into dry, obtain Caulis Sargentodoxae extract.Get Fluoritum 6kg, pulverizing, cross 60 mesh sieves, obtain Fluoritum powder for subsequent use.Get drying 6kg Radix Ophiopogonis, add the Diluted Alcohol of 3 times of volumes, decoct 5 hours, filter, collect filtrate, the filtering residue dense alcohol reflux 1 hour using 2 times of volumes again, filter, merging filtrate, the middle ethanol contend percentage ratio adding ethanol adjustment solution reaches more than 80%, supernatant concentration, to dry, obtains Radix Ophiopogonis extract.Get Semen Phaseoli 3kg, it is for subsequent use that pulverize at low temperature obtains Semen Phaseoli powder.The various extracts obtained through above-mentioned steps process are mixed in proportion, make tablet.The acceptable adjuvant of appropriate pharmacy can be added according to actual needs.
Embodiment 7
Get Radix Astragali 35kg, Fructus Choerospondiatis 12kg, Caulis Sargentodoxae 6kg, Fluoritum 8kg, Radix Ophiopogonis 2kg, Semen Phaseoli 8kg, implementation process, with embodiment 6, adds appropriate forming agent, binding agent tabletted.
Embodiment 8
By Radix Astragali 18kg, add the high concentration ethanol of 6 times of volumes, reflux, extract, 3 times, each 2 hours, merge extractive liquid, is concentrated into dry, obtains Radix Astragali extract.Get Fructus Choerospondiatis 6kg, it is for subsequent use that pulverize at low temperature obtains Fructus Choerospondiatis powder.Get Caulis Sargentodoxae 6kg, section, add the alcohol reflux 2 hours of 30% of 1 times of volume ratio, filter, collect filtrate, repeat to extract once, merging filtrate, filtrate crosses polyamide column, first rinse colourless to effluent with water, then use straight alcohol eluting, collect ethanol elution, be concentrated into dry, obtain Caulis Sargentodoxae extract.Get Fluoritum 6kg, pulverizing, cross 60 mesh sieves, obtain Fluoritum powder for subsequent use.Get drying 6kg Radix Ophiopogonis, add the Diluted Alcohol of 3 times of volumes, decoct 4 hours, filter, collect filtrate, the filtering residue dense alcohol reflux 2 hours using 2 times of volumes again, filter, merging filtrate, the middle ethanol contend percentage ratio adding ethanol adjustment solution reaches more than 80%, supernatant concentration, to dry, obtains Radix Ophiopogonis extract.Get Semen Phaseoli 3kg, it is for subsequent use that pulverize at low temperature obtains Semen Phaseoli powder.The various extracts obtained through above-mentioned steps process are mixed in proportion, make tablet.The acceptable adjuvant of appropriate pharmacy can be added according to actual needs.
Embodiment 9
Use the extract mixtures identical with embodiment 8, be prepared into capsule.
Claims (4)
1. treat a pharmaceutical composition for cardiovascular and cerebrovascular disease, it is characterized in that being prepared from primarily of the Radix Astragali, Fructus Choerospondiatis, Caulis Sargentodoxae, Fluoritum, Radix Ophiopogonis, Semen Phaseoli.
2. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 1, it is characterized in that the ratio of each component is: Radix Astragali 1-35 part, Fructus Choerospondiatis 1-12 part, Caulis Sargentodoxae 1-12 part, Fluoritum 1-12 part, Radix Ophiopogonis 1-12 part, Semen Phaseoli 1-8 part.
3. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 2, it is characterized in that the ratio of each component is: Radix Astragali 10-30 part, Fructus Choerospondiatis 2-8 part, Caulis Sargentodoxae 2-8 part, Fluoritum 2-8 part, Radix Ophiopogonis 2-8 part, Semen Phaseoli 1-5 part.
4. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 3, it is characterized in that the ratio of each component is: the Radix Astragali 18 parts, Fructus Choerospondiatis 6 parts, Caulis Sargentodoxae 6 parts, Fluoritum 6 parts, Radix Ophiopogonis 6 parts, Semen Phaseoli 3 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410632859.4A CN104435664A (en) | 2014-11-11 | 2014-11-11 | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410632859.4A CN104435664A (en) | 2014-11-11 | 2014-11-11 | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104435664A true CN104435664A (en) | 2015-03-25 |
Family
ID=52882925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410632859.4A Pending CN104435664A (en) | 2014-11-11 | 2014-11-11 | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435664A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114767743A (en) * | 2022-05-09 | 2022-07-22 | 河南省芝元堂药业有限公司 | Chinese patent medicine containing red sage root for treating cardiovascular and cerebrovascular diseases and preparation process of Chinese patent medicine preparation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546048A (en) * | 2003-12-02 | 2004-11-17 | 李文军 | Cardiac and cerebral vascular disease treating medicinal composition |
| CN1562057A (en) * | 2004-03-31 | 2005-01-12 | 成都和康药业有限责任公司 | Medicinal composition for treating cardiocerobral diseases |
| CN102940657A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN102940668A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
-
2014
- 2014-11-11 CN CN201410632859.4A patent/CN104435664A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546048A (en) * | 2003-12-02 | 2004-11-17 | 李文军 | Cardiac and cerebral vascular disease treating medicinal composition |
| CN1562057A (en) * | 2004-03-31 | 2005-01-12 | 成都和康药业有限责任公司 | Medicinal composition for treating cardiocerobral diseases |
| CN102940657A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN102940668A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
Non-Patent Citations (4)
| Title |
|---|
| 李东晓等: "《心脑血管疾病临床常用中药指南》", 28 February 2006, 科学技术文献出版社 * |
| 李怀珍等: "老年心脑血管病的中医治疗初探", 《陕西中医》 * |
| 王友民等: "心脑血管疾病中医病因病机探析", 《陕西中医学院学报》 * |
| 陶春祥: "论老年病与肾虚血瘀", 《辽宁中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114767743A (en) * | 2022-05-09 | 2022-07-22 | 河南省芝元堂药业有限公司 | Chinese patent medicine containing red sage root for treating cardiovascular and cerebrovascular diseases and preparation process of Chinese patent medicine preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104606513A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN104367630A (en) | American ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104367656A (en) | Hawthorn leaf-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN101987112A (en) | Medicine composition for treating cardio-cerebrovascular diseases and preparation method thereof | |
| CN104435664A (en) | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104587166A (en) | Traditional Chinese medicine preparation for treating postpartum, and preparation method | |
| CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN102940675B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940676B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940657A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN104435106A (en) | Medicine composition containing salviae miltiorrhizae for treating cardiovascular and cerebrovascular diseases | |
| CN104435107A (en) | Rhizoma-chuanxiong-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104367725A (en) | Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN103800874B (en) | A kind of pharmaceutical composition of fumigation treatment apoplexy hemiplegia limbs disturbance | |
| CN104367618A (en) | Fructus choerospondiatis-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104435080A (en) | Ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104435074A (en) | Rhodiola-rosea-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN107468958A (en) | Treat the medicine of varix of lower limb | |
| CN116098940A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN104435164A (en) | Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN105169129A (en) | Zhuang medicine composition for treating hypertension and preparation method thereof | |
| CN100381125C (en) | Cardiac and cerebral vascular disease treating medicinal composition | |
| CN113082099A (en) | Traditional Chinese medicine composition for treating hypertension by external application and preparation method and application thereof | |
| CN108524760A (en) | It is a kind of to be used to treat compound Chinese medicinal preparation of peripheral vascular disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150325 |